Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease

NCT00769704 is registered in ClinicalTrials.gov with BioVex Limited as lead sponsor.

NCT NCT00769704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00769704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Lead sponsor
BioVex Limited
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2009
Completion date
September 30, 2014
Enrollment
437 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma